<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="234">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856359</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00093318</org_study_id>
    <nct_id>NCT03856359</nct_id>
  </id_info>
  <brief_title>Trial of Rifaximin in Probable Alzheimer's Disease</brief_title>
  <official_title>Pilot, Single Center, Open, Trial of Rifaximin in Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to improve cognition and function in patients with Alzheimer's Disease (AD)&#xD;
      by administering the oral antibiotic, Rifaximin.&#xD;
&#xD;
      Rifaximin is a virtually non-absorbed antibiotic with the unique properties of lowering blood&#xD;
      ammonia levels and altering gut microbiota. It is FDA approved for use in patients with&#xD;
      hepatic encephalopathy. Rifaximin lowers blood ammonia by altering fecal flora by blocking&#xD;
      bacterial RNA synthesis and also by increasing small bowel glutaminase. The Investigators&#xD;
      hypothesize that rifaximin will improve cognition and function in AD patients by lowering&#xD;
      blood ammonia and / or lowering circulatory pro-inflammatory cytokines secreted by harmful&#xD;
      gut bacteria. The Investigators will enroll up to 10 subjects with probable middle stage&#xD;
      Alzheimer's Disease. The subjects will be given rifaximin 550 mg orally twice daily for 3&#xD;
      months after evaluation to ensure they have no contraindications. Physician clinical and&#xD;
      safety assessments, adverse events, as well as the ADAS-Cog-11 will be administered at&#xD;
      baseline and at the 3 month endpoint and two months after stopping treatment (at month 5).&#xD;
      Interim safety checks will occur via phone calls one week after baseline and then every 2&#xD;
      weeks till end point. Serum neuronal biomarkers, ammonia levels and pro-inflammatory and&#xD;
      anti-inflammatory compounds will also be measured at those times. Bodily fluids (Stool&#xD;
      samples) will also be collected. Because of a small risk of developing C. difficile up to 2&#xD;
      months following the last administration of rifaximin, the subjects will be followed for an&#xD;
      additional 2 months after the 3 month treatment ends.&#xD;
&#xD;
      Rifaximin is contraindicated in patients with hypersensitivity to rifaximin or rifamycin&#xD;
      antimicrobials. Hypersensitivity reactions include exfoliative dermatitis, angioneurotic&#xD;
      edema, and anaphylaxis. Clostridium difficile associated diarrhea is a risk whenever a&#xD;
      patient is maintained chronically on antibiotics, with complications ranging from mild&#xD;
      diarrhea to fatal colitis. Drug resistant bacteria can also result from long term use. There&#xD;
      is increased systemic exposure to rifaximin in patients with severe hepatic impairment or in&#xD;
      patients who are taking P-glycoprotein inhibitors concomitantly. Regarding use in geriatric&#xD;
      patients, there were no reported overall differences in the safety of the drug when used in&#xD;
      patients 65 years of age or over, when compared with younger subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to improve cognition and function in patients with Alzheimer's Disease (AD)&#xD;
      by administering the oral antibiotic, rifaximin. Rifaximin is a virtually non-absorbed&#xD;
      antibiotic with the unique properties of altering gut microbiota and lowering blood ammonia&#xD;
      levels. It is FDA approved for use in patients with hepatic encephalopathy. Rifaximin lowers&#xD;
      blood ammonia by blocking gut bacterial RNA synthesis and also by increasing small bowel&#xD;
      glutaminase. The Investigators hypothesize that rifaximin will improve cognition and function&#xD;
      in AD patients by mechanisms such as lowering circulatory pro-inflammatory cytokines secreted&#xD;
      by harmful gut bacteria or lowering blood ammonia.&#xD;
&#xD;
      Rifaximin is a relatively gut-specific antibiotic that interferes with by binding to the&#xD;
      transcription subunit of bacterial . Because Rifaximin is absorbed poorly, most of the drug&#xD;
      taken RNA polymerase orally stays in the gastrointestinal tract. It has been available since&#xD;
      2004 in the US and has orphan gastrointestinal tract drug status for hepatic encepalopathy.&#xD;
      Rifaximin's relatively good safety profile and its ability to alter gut flora and lower blood&#xD;
      ammonia have made it an attractive drug to treat hepatic encephalopathy or conditions such as&#xD;
      traveller's diarrhea. The Investigators hypothesize that rifaximin will improve cognition and&#xD;
      function in AD patients by mechanisms such as lowering circulatory pro-inflammatory cytokines&#xD;
      secreted by harmful gut bacteria or lowering blood ammonia.&#xD;
&#xD;
      The Investigators will measure a variety of blood markers, such as pro-inflammatory and&#xD;
      anti-inflammatory compounds, and analyze fecal microbiota in patients with AD before and&#xD;
      after 3 months of rifaximin therapy. If patients exhibit measurable improvement in cognition&#xD;
      and function, The Investigators will analyze our data to see if their improvement correlates&#xD;
      with a shift towards anti-inflammatory species in the gut and a similar shift in the blood&#xD;
      cytokine panel to favoring anti-inflammatory compounds.&#xD;
&#xD;
      Evidence supporting our hypothesis for this study is presented below.&#xD;
&#xD;
      Gut Microbiota Dysbiosis&#xD;
&#xD;
      The gut harbors 95% of the total human microbiome and is made up of more than 5,000 taxa. Gut&#xD;
      species remain relatively constant throughout adulthood until the seventh decade, when it&#xD;
      becomes less diverse, harboring higher numbers of Proteobacteria and lower numbers of&#xD;
      Bifidobacteria. An imbalance in the gut bacterial species can weaken the intestinal barrier&#xD;
      and create system wide inflammation via gut lymphoid tissue which comprises 70% - 80% of the&#xD;
      immune system. Blood brain barrier permeability is also altered. The gut bacteria secrete&#xD;
      pro-inflammatory compounds and neuroactive molecules that include serotonin,&#xD;
      gamma-aminobutyric acid (GABA), catecholamines and acetylcholine which cross the blood brain&#xD;
      barrier and cause brain inflammation and brain dysfunction.&#xD;
&#xD;
      A growing number of pro-inflammatory compounds secreted by gut bacteria and seen in patients&#xD;
      with AD are being discovered. These include interleukin (IL) - 6, tumor necrosis - alpha and&#xD;
      the inflammasome complex (NLRP3). A recent study revealed higher numbers of Escherichia and&#xD;
      Shigella in the gut of amyloid positive AD patients when compared with healthy controls and&#xD;
      this correlated with higher levels of circulating pro-inflammatory cytokines. The AD patients&#xD;
      also had lower numbers of gut Eubacterium rectale and this correlated with lower levels of&#xD;
      circulating anti-inflammatory compounds than seen in controls. Other researchers found that a&#xD;
      preponderance of gut Bacteroides and Blautia and reduced numbers of SMB53 and Dialister&#xD;
      correlated with elevated levels of brain amyloid Cerebrospinal Fluid (CSF) biomarkers.&#xD;
      Interestingly, Clostridium tyrobutyricum and Bacteroides thetaiotaomicron, have been shown to&#xD;
      actually increase the integrity of the blood brain barrier by enhancing expression of tight&#xD;
      junction proteins and helping to maintain brain homeostasis. Recent evidence also suggests&#xD;
      that neurotransmitters and neuropeptides secreted by bacteria in the gut activate vagal nerve&#xD;
      ascending fibers, influencing brain function.&#xD;
&#xD;
      Ammonia Neurotoxicity&#xD;
&#xD;
      A second theory is that the blood brain barrier allows greater amounts of ammonia into the AD&#xD;
      brain, triggering or worsening pre-existent changes. The possibility that ammonia is at least&#xD;
      partly responsible for the pathologic changes seen in the AD brain was first proposed by&#xD;
      Seiler in 1993, when he noted that some of the changes in the AD brain can also be seen in&#xD;
      the brains of hyperammonemic patients. Arteriovenous sampling in early stage normoammonemic&#xD;
      AD patients demonstrated higher endogenous cortical ammonia compared to young control&#xD;
      subjects Low glutamine synthetase levels have been found to correlate with increased density&#xD;
      of amyloid deposits in the AD brain.&#xD;
&#xD;
      The brain also receives exogenous ammonia, of which the gut is a major source. The aging&#xD;
      colon contains a greater percentage of protein fermenting bacteria than is seen in the colon&#xD;
      of younger patients.&#xD;
&#xD;
      Rifaximin lowers blood ammonia by altering fecal flora by blocking bacterial RNA synthesis&#xD;
      and also by increasing small bowel glutaminase.&#xD;
&#xD;
      The Investigators hypothesize that Rifaximin will improve cognition and function in AD&#xD;
      patients by lowering circulatory pro-inflammatory cytokines secreted by harmful gut bacteria&#xD;
      and / or lowering blood ammonia levels. The subjects will be given rifaximin 550 mg orally&#xD;
      twice daily for 3 months after evaluation to ensure they have no contraindications. Physician&#xD;
      clinical and safety assessments, adverse events, as well as the ADAS-Cog11 will be&#xD;
      administered at baseline and at the 3 month endpoint. Interim safety checks will occur via&#xD;
      phone calls one week after baseline and then every 2 weeks till 3 month end point. Serum&#xD;
      neuronal biomarkers, ammonia levels and pro-inflammatory and antiinflammatory compounds will&#xD;
      also be measured at those times. Bodily fluids (Stool samples) will also be collected.&#xD;
      Because of a small risk of developing C. difficile up to 2 months following the last&#xD;
      administration of rifaximin, the subjects will be followed for an additional 2 months after&#xD;
      the 3 month treatment ends.&#xD;
&#xD;
      This is an open label pilot study designed to provide preliminary evidence on the clinical&#xD;
      efficacy of rifaximin in improving cognition in AD patients. The Investigators will be&#xD;
      looking for improvement in test scores and changes in serum levels of neuronal markers,&#xD;
      circulating cytokine pro-inflammatory compounds and colonic microbiota following treatment.&#xD;
      The Investigators will also be collecting data regarding the safety of long term use of this&#xD;
      non-absorbed antibiotic for this disease. This pilot may form the basis for a future larger&#xD;
      randomized, double blind controlled study to further test this hypothesis.&#xD;
&#xD;
      The rifaximin dosage and route of administration are the same as that used to treat hepatic&#xD;
      encephalopathy, for which the drug and dosage are FDA approved. The dose will remain the same&#xD;
      throughout the 3 month study of rifaximin administration unless stopped for safety reasons.&#xD;
      The age and study sample of mild to moderate probable AD is similar to that used in AD prior&#xD;
      trials. The Investigators will select our sample to be medically stable and free of hepatic&#xD;
      disease and not having had recent antibiotic therapy to minimize risk for C Difficile&#xD;
      infection.&#xD;
&#xD;
      The end of the study will occur 5 months after baseline testing and first administration of&#xD;
      the drug. While drug administration will conclude and endpoint testing will be done at 3&#xD;
      months, The Investigators will continue to follow each subject for an additional 2 months, as&#xD;
      C. difficile infectious diarrhea can occur up until 2 months after stopping an antibiotic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile</measure>
    <time_frame>5 months</time_frame>
    <description>Collected at every visit and follow-up phone visits. A rare side effect of Rifaximin is diarrhea caused by clostridium difficile. This is a very serious form of diarrhea that can be fatal if not treated. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ADAS Cog 11 Scores</measure>
    <time_frame>At baseline and at 3 months</time_frame>
    <description>Change in Alzheimer's Disease Assessment Scale - Cognition test with 11 tasks (ADAS Cog 11) scores following 3 months of oral Rifaximin. Scores range from minimum 0 - maximum 70. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Tolerability as Measured by Number of Adverse Events (AE).</measure>
    <time_frame>Baseline, 3 months, 5 months</time_frame>
    <description>Assessed at every visit. The patients will be followed closely to see if they are tolerating the drug, Rifaximin. The of the number of side effects would indicate that the patient may not be tolerating the drug. Most of these side effects are minor and include headache, nausea, vomiting, tiredness. A potentially fatal side effect would be the development of clostridium difficile diarrhea. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Performance on the Mini-Mental State Exam (MMSE)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change from baseline global cognitive scores at month 3). Global cognitive performance will be assessed by a psychometrician using the (MMSE). It is a brief cognitive questionnaire with a maximum score of 30 points. MMSE range is 0-30 with lower scores indicating worse performance. The number of correct answers is added to generate the total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment Emergent Adverse Events as Reported by the Subject That Required a Change in Safety Measures</measure>
    <time_frame>Safety will be measured through adverse events throughout study, at month 3 and by phone call at month 5 (2 months after treatment termination).</time_frame>
    <description>Emergent AEs that required a change in safety measures. These were AEs that were found when talking to or examining the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Ammonia Level</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in ammonia levels following treatment with Rifaximin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Clostridium Difficile Diarrhea</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Observing for development of diarrhea due to Clostridium difficile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Tau</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in serum Total tau after 3 months Rifaximin administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylated Tau</measure>
    <time_frame>at baseline and at 3 months</time_frame>
    <description>Change in Phosphorylated tau following 3 months oral Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glial Fibrillary Acidic Protein (GFAP)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Glial Fibrillary Acidic Protein (GFAP) after 3 months of oral Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neurofilament Light (Nfl) Levels</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Neurofilament Light levels after Rifaximin for 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 10 (IL-10)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Interleukin 10 following 3 months Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Interleukin 13 (IL-13) Following Treatment With Rifaximin</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Interleukin 13 levels after Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 1B (IL-1B)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Interleukin 1B following Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 2 (IL-2)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Interleukin 2 following Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 4 (IL-4)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Interleukin 4 after Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 5 (IL-5)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Interleukin 5 after Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 8 (IL-8)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Interleukin 8 after Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin 6 (IL-6)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Interleukin 6 following Rifaximin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Necrosis Factor a</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Change in Tumor Necrosis Factor a</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin 550 milligrams (MG)</intervention_name>
    <description>Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
    <arm_group_label>Rifaximin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Â· Probable Alzheimer's Disease (National Institute of Neurological Disorders and&#xD;
             Stroke (NINDS) criteria), mild to moderate severity&#xD;
&#xD;
               -  Ages 55-85; both genders&#xD;
&#xD;
               -  Mini Mental State Exam (MMSE) scores 10-23&#xD;
&#xD;
               -  Willing and able to comply with all scheduled clinic visits.&#xD;
&#xD;
               -  Stable medical health&#xD;
&#xD;
               -  Has a family or professional caregiver who has regular contact with subject&#xD;
&#xD;
               -  Ability to consent or legal guardian who can consent&#xD;
&#xD;
               -  Living at home or in a facility&#xD;
&#xD;
               -  On no AD therapies or on stable (2 months) concurrent AD therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past history of C diff infection&#xD;
&#xD;
          -  Assessment, laboratory examination, physical examination or any other medical&#xD;
             condition or circumstance making the volunteer unsuitable for participation in the&#xD;
             study in the judgment of the study clinicians&#xD;
&#xD;
          -  Allergy to Rifaximin&#xD;
&#xD;
          -  Antibiotic use or hospitalization in the last 6 months&#xD;
&#xD;
          -  Are taking medications that interact with rifaximin and/or pose a safety risk in the&#xD;
             judgment of the PI&#xD;
&#xD;
          -  Clinically significant abnormal hepatic or renal function&#xD;
&#xD;
          -  Uncorrected thyroid or B12 abnormalities&#xD;
&#xD;
          -  Participation in another investigational drug trial in the past 30 days&#xD;
&#xD;
          -  History of febrile illness within 5 days prior to the study period&#xD;
&#xD;
          -  Known Hyperammonemia caused by:&#xD;
&#xD;
        Valproic acid Chemotherapy Lung transplant Bariatric surgery Ureterosigmoidoscopy&#xD;
        Hyperalimentation Urinary tract infection Errors of metabolism: urea cycle, enzyme&#xD;
        deficiencies, organic acidemias, fatty acid oxidation, amino acid transport defects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Suhocki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <results_first_submitted>November 18, 2021</results_first_submitted>
  <results_first_submitted_qc>November 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2021</results_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03856359/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03856359/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03856359/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from referrals and the community via advertisement. Subjects and caregivers compensated for participation in the study to cover travel and time.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rifaximin</title>
          <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rifaximin</title>
          <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="50" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile</title>
        <description>Collected at every visit and follow-up phone visits. A rare side effect of Rifaximin is diarrhea caused by clostridium difficile. This is a very serious form of diarrhea that can be fatal if not treated. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile</title>
          <description>Collected at every visit and follow-up phone visits. A rare side effect of Rifaximin is diarrhea caused by clostridium difficile. This is a very serious form of diarrhea that can be fatal if not treated. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in ADAS Cog 11 Scores</title>
        <description>Change in Alzheimer's Disease Assessment Scale - Cognition test with 11 tasks (ADAS Cog 11) scores following 3 months of oral Rifaximin. Scores range from minimum 0 - maximum 70. Higher scores mean worse outcome.</description>
        <time_frame>At baseline and at 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ADAS Cog 11 Scores</title>
          <description>Change in Alzheimer's Disease Assessment Scale - Cognition test with 11 tasks (ADAS Cog 11) scores following 3 months of oral Rifaximin. Scores range from minimum 0 - maximum 70. Higher scores mean worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="30.3" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tolerability as Measured by Number of Adverse Events (AE).</title>
        <description>Assessed at every visit. The patients will be followed closely to see if they are tolerating the drug, Rifaximin. The of the number of side effects would indicate that the patient may not be tolerating the drug. Most of these side effects are minor and include headache, nausea, vomiting, tiredness. A potentially fatal side effect would be the development of clostridium difficile diarrhea. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
        <time_frame>Baseline, 3 months, 5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tolerability as Measured by Number of Adverse Events (AE).</title>
          <description>Assessed at every visit. The patients will be followed closely to see if they are tolerating the drug, Rifaximin. The of the number of side effects would indicate that the patient may not be tolerating the drug. Most of these side effects are minor and include headache, nausea, vomiting, tiredness. A potentially fatal side effect would be the development of clostridium difficile diarrhea. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Performance on the Mini-Mental State Exam (MMSE)</title>
        <description>Change from baseline global cognitive scores at month 3). Global cognitive performance will be assessed by a psychometrician using the (MMSE). It is a brief cognitive questionnaire with a maximum score of 30 points. MMSE range is 0-30 with lower scores indicating worse performance. The number of correct answers is added to generate the total score.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Performance on the Mini-Mental State Exam (MMSE)</title>
          <description>Change from baseline global cognitive scores at month 3). Global cognitive performance will be assessed by a psychometrician using the (MMSE). It is a brief cognitive questionnaire with a maximum score of 30 points. MMSE range is 0-30 with lower scores indicating worse performance. The number of correct answers is added to generate the total score.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.8" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Treatment Emergent Adverse Events as Reported by the Subject That Required a Change in Safety Measures</title>
        <description>Emergent AEs that required a change in safety measures. These were AEs that were found when talking to or examining the subjects.</description>
        <time_frame>Safety will be measured through adverse events throughout study, at month 3 and by phone call at month 5 (2 months after treatment termination).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment Emergent Adverse Events as Reported by the Subject That Required a Change in Safety Measures</title>
          <description>Emergent AEs that required a change in safety measures. These were AEs that were found when talking to or examining the subjects.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Ammonia Level</title>
        <description>Change in ammonia levels following treatment with Rifaximin.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Ammonia Level</title>
          <description>Change in ammonia levels following treatment with Rifaximin.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-7.06" upper_limit="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Clostridium Difficile Diarrhea</title>
        <description>Observing for development of diarrhea due to Clostridium difficile</description>
        <time_frame>Baseline to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Clostridium Difficile Diarrhea</title>
          <description>Observing for development of diarrhea due to Clostridium difficile</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Tau</title>
        <description>Change in serum Total tau after 3 months Rifaximin administration.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Tau</title>
          <description>Change in serum Total tau after 3 months Rifaximin administration.</description>
          <units>ng/mL</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-0.61" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phosphorylated Tau</title>
        <description>Change in Phosphorylated tau following 3 months oral Rifaximin</description>
        <time_frame>at baseline and at 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphorylated Tau</title>
          <description>Change in Phosphorylated tau following 3 months oral Rifaximin</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-1.07" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glial Fibrillary Acidic Protein (GFAP)</title>
        <description>Change in Glial Fibrillary Acidic Protein (GFAP) after 3 months of oral Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glial Fibrillary Acidic Protein (GFAP)</title>
          <description>Change in Glial Fibrillary Acidic Protein (GFAP) after 3 months of oral Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.76" lower_limit="-99.46" upper_limit="19.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurofilament Light (Nfl) Levels</title>
        <description>Change in Neurofilament Light levels after Rifaximin for 3 months</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neurofilament Light (Nfl) Levels</title>
          <description>Change in Neurofilament Light levels after Rifaximin for 3 months</description>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" lower_limit="-6.71" upper_limit="-1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 10 (IL-10)</title>
        <description>Change in Interleukin 10 following 3 months Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 10 (IL-10)</title>
          <description>Change in Interleukin 10 following 3 months Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="00.70" lower_limit="-4.85" upper_limit="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Interleukin 13 (IL-13) Following Treatment With Rifaximin</title>
        <description>Interleukin 13 levels after Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Interleukin 13 (IL-13) Following Treatment With Rifaximin</title>
          <description>Interleukin 13 levels after Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" lower_limit="-3.9" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 1B (IL-1B)</title>
        <description>Change in Interleukin 1B following Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 1B (IL-1B)</title>
          <description>Change in Interleukin 1B following Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-2.06" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 2 (IL-2)</title>
        <description>Change in Interleukin 2 following Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>10 patients with Alzheimer's Disease</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 2 (IL-2)</title>
          <description>Change in Interleukin 2 following Rifaximin</description>
          <population>10 patients with Alzheimer's Disease</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.93" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 4 (IL-4)</title>
        <description>Change in Interleukin 4 after Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 4 (IL-4)</title>
          <description>Change in Interleukin 4 after Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.40" lower_limit="-68.73" upper_limit="33.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 5 (IL-5)</title>
        <description>Change in Interleukin 5 after Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 5 (IL-5)</title>
          <description>Change in Interleukin 5 after Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" lower_limit="-2.34" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 8 (IL-8)</title>
        <description>Change in Interleukin 8 after Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 8 (IL-8)</title>
          <description>Change in Interleukin 8 after Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" lower_limit="-5.81" upper_limit="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin 6 (IL-6)</title>
        <description>Change in Interleukin 6 following Rifaximin</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 6 (IL-6)</title>
          <description>Change in Interleukin 6 following Rifaximin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" lower_limit="-3.39" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tumor Necrosis Factor a</title>
        <description>Change in Tumor Necrosis Factor a</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor a</title>
          <description>Change in Tumor Necrosis Factor a</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" lower_limit="-1.55" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rifaximin</title>
          <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months&#xD;
Rifaximin 550 milligrams (MG): Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upset stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fell out of chair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Decline in cognitive ability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Increased confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hand tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul V. Suhocki</name_or_title>
      <organization>Duke University Hospital</organization>
      <phone>919-684-7284</phone>
      <email>suhoc001@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

